Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 2;21(12):1757-1764.
doi: 10.1158/1535-7163.MCT-22-0323.

JAK: Not Just Another Kinase

Affiliations
Review

JAK: Not Just Another Kinase

Ruchi P Agashe et al. Mol Cancer Ther. .

Abstract

The JAK/STAT axis is implicated in cancer, inflammation, and immunity. Numerous cytokines/growth factors affect JAK/STAT signaling. JAKs (JAK1, JAK2, JAK3, and TYK2) noncovalently associate with cytokine receptors, mediate receptor tyrosine phosphorylation, and recruit ≥1 STAT proteins (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6). Tyrosine-phosphorylated STATs dimerize and are then transported into the nucleus to function as transcription factors. Signaling is attenuated by specific suppressor of cytokine signaling proteins, creating a negative feedback loop. Both germline mutations and polymorphisms of JAK family members correlate with specific diseases: Systemic lupus erythematosus (TYK2 polymorphisms); severe combined immunodeficiency (JAK3 mutations); pediatric acute lymphoblastic leukemia (TYK2 mutations); and hereditary thrombocytosis (JAK2 mutations). Somatic gain-of-function JAK mutations mainly occur in hematologic malignancies, with the activating JAK2 V617F being a myeloproliferative disorder hallmark; it is also seen in clonal hematopoiesis of indeterminate potential. Several T-cell malignancies, as well as B-cell acute lymphoblastic leukemia, and acute megakaryoblastic leukemia also harbor JAK family somatic alterations. On the other hand, JAK2 copy-number loss is associated with immune checkpoint inhibitor resistance. JAK inhibitors (jakinibs) have been deployed in many conditions with JAK activation; they are approved in myeloproliferative disorders, rheumatoid and psoriatic arthritis, atopic dermatitis, ulcerative colitis, graft-versus-host disease, alopecia areata, ankylosing spondylitis, and in patients hospitalized for COVID-19. Clinical trials are investigating jakinibs in multiple other autoimmune/inflammatory conditions. Furthermore, dermatologic and neurologic improvements have been observed in children with Aicardi-Goutieres syndrome (a genetic interferonopathy) treated with JAK inhibitors.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Dr. Lippman is on the scientific advisory board for Biological Dynamics and co-founded io9. Dr. Kurzrock has received research funding from Biological Dynamics, Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Takeda, and TopAlliance; as well as consultant and/or speaker fees and/or advisory board for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Biological Dynamics, Daiichi Sankyo, Inc., EISAI, EOM Pharmaceuticals, Iylon, Merck, NeoGenomics, Neomed, Pfizer, Prosperdtx, Roche, TD2/Volastra, Turning Point Therapeutics, X-Biotech; has an equity interest in CureMatch Inc., CureMetrix, and IDbyDNA; serves on the Board of CureMatch and CureMetrix,and is a co-founder of CureMatch.

Figures

Figure 1:
Figure 1:. Functional Roles of JAK1, JAK2, JAK3, TYK2/STAT Pathways:
There are several members of the JAK family and the TYK protein that are involved in the JAK/STAT pathway. Some examples are shown. Important roles of these pathways include enhanced regulatory response and immune system regulation, myeloid and lymphoid differentiation/proliferation, and proinflammatory response (–27) Abbreviations: IFN- interferon; IL- interleukin; JAK- Janus kinase; STAT- signal transducer and activator of transcription; TYK- tyrosine kinase

References

    1. Muller R JAK inhibitors in 2019, synthetic review in 10 points. Eur J Intern Med 2019;66:9–17. doi: 10.1016/j.ejim.2019.05.022. - DOI - PubMed
    1. Bousoik E, Montazeri Aliabadi H . Do We Know Jack About JAK? A Closer Look at JAK/STAT Signaling Pathway. Front Oncol 2018;8:287. doi: 10.3389/fonc.2018.00287. - DOI - PMC - PubMed
    1. Loh CY, Arya A, Naema AF, Wong WF, Sethi G, Looi CY. Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication . Front Oncol 2019;9:48. doi:10.3389/fonc.2019.00048 - DOI - PMC - PubMed
    1. Morris R, Kershaw NJ, Babon JJ. The molecular details of cytokine signaling via the JAK/STAT pathway. Protein Sci 2018;27:1984–2009. doi: 10.1002/pro.3519. - DOI - PMC - PubMed
    1. Fragoulis GE, McInnes IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. Rheumatology (Oxford) 2019;58(Suppl 1):i43–i54. doi: 10.1093/rheumatology/key276. - DOI - PMC - PubMed

Publication types